High Positive Rate of pS2 Expression in Forefront Intraductal Cancerous Area in Breast Cancer

Multiple sections of 40 consecutive cases with invasive ductal carcinoma of the breast, all of which had wide intraductal cancerous extension, were examined by immunohistochemicsl analysis for evaluation of hormone dependency in several areas of breast cancer tissues. In this study, we examined the...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 1995-11, Vol.86 (11), p.1035-1040
Main Authors: Yamakawa, Takashi, Morimoto, Tadaoki, Sasa, Mitsunori, Numoto, Satoshi, Monden, Yasumasa
Format: Article
Language:English
Subjects:
Biological and medical sciences
Breast cancer
Breast conserving treatment
Breast Neoplasms - chemistry
Breast Neoplasms - pathology
Carcinoma, Ductal, Breast - chemistry
Carcinoma, Ductal, Breast - pathology
Comedones
Endocrine therapy
Estrogen receptor
Estrogen receptors
Estrogens
Female
Gynecology. Andrology. Obstetrics
Hormone dependency
Humans
Invasiveness
Mammary gland diseases
Medical sciences
Menopause
Neoplasm Invasiveness
Neoplasm Proteins - analysis
Neoplasms, Hormone-Dependent - metabolism
Neoplasms, Hormone-Dependent - pathology
Presenilin 2
Proteins
pS2 protein
Receptors, Estrogen - analysis
Trefoil Factor-1
Tumor Suppressor Proteins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple sections of 40 consecutive cases with invasive ductal carcinoma of the breast, all of which had wide intraductal cancerous extension, were examined by immunohistochemicsl analysis for evaluation of hormone dependency in several areas of breast cancer tissues. In this study, we examined the expression of pS2 protein in the central invasive area (CIV), central intraductal cancerous area (CDC) and forefront intraductal cancerous area (FDC). pS2 staining was positive in 52.5% (21/40) of CIV and a significant correlation was found between pS2 expression in CIV and the estrogen receptor status (ER). pS2 staining was positive in 77.5% of CDC and 85.0% of FDC, respectively. A majority (68.4%) of the cases that were negative pS2 in CIV were positive for pS2 in FDC. Moreover, the cases with noncomedo intraductal carcinoma in premenopausal status showed a higher positivity of pS2 expression in FDC than the cases with comedo‐carcinoma, though the number of cases of comedo‐carcinoma was limited. These findings suggest that endocrine therapy may be useful after breast conserving treatment regardless of the ER status of the primary tumor.
ISSN:0910-5050
1347-9032
1349-7006
1876-4673
DOI:10.1111/j.1349-7006.1995.tb03017.x